Skip to main content

Fenimore Christopher R.'s Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Aug 24, 2021

Accession no.
0001237899-21-000017
Filed
Aug 24, 2021
Trade date
Aug 20-23, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.13M. It was filed 4 days after the trade.

This filing was later replaced by the amendment 0001104659-21-109328 (Aug 25, 2021). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Fenimore Christopher R.CIK 0001697422Officer (SVP Controller)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 20, 2021Common StockMOption exerciseAcquired+13,500$179.13+$2,418,25532,520Direct
Aug 23, 2021Common StockSSaleDisposed−4,576$655.00−$2,997,28027,944Direct
Aug 23, 2021Common StockSSaleDisposed−9$659.33F2−$5,933.9727,935Direct
Aug 23, 2021Common StockSSaleDisposed−23$660.33F3−$15,187.5927,912Direct
Aug 23, 2021Common StockSSaleDisposed−88$661.89F4−$58,246.3227,824Direct
Aug 23, 2021Common StockSSaleDisposed−1$662.78−$662.7827,823Direct
Aug 23, 2021Common StockSSaleDisposed−70$663.05F5−$46,413.527,753Direct
Aug 23, 2021Common StockSSaleDisposed−14$665.21−$9,312.9427,739Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 20, 2021Common StockMOption exerciseDisposed−13,500$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents volume-weighted average price of sales of 9 shares of Company stock on August 23, 2021 at prices ranging from $659.28 to $659.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents volume-weighted average price of sales of 23 shares of Company stock on August 23, 2021 at prices ranging from $660.09 to $660.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents volume-weighted average price of sales of 88 shares of Company stock on August 23, 2021 at prices ranging from $661.47 to $661.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents volume-weighted average price of sales of 70 shares of Company stock on August 23, 2021 at prices ranging from $663.00 to $663.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)